NDA 218922 · Cipla
Nilotinib D-Tartrate
Nilotinib D-Tartrate · Oral · Kinase Inhibitor
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Feb 19, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
1 Phase 3, 1 recruiting
FAERS reports
4,067
3,797 serious, 635 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: QT PROLONGATION and SUDDEN DEATHS Nilotinib prolongs the QT interval. Prior to Nilotinib Capsules administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies [see Warnings and Precautions ( 5.2 )]. Obtain ECGs to monitor the QTc at baseline, seven days after initiation, and periodically thereafter, and following any dose adjustments [see Warnings and Precautions ( 5.2 , 5.3 , 5.7 , 5.12 )]. Sudden deaths have been reported in patients receiving nilotinib [see Warnings and Precautions ( 5.3 )]. Do not administer Nilotinib Capsules to patients with hypokalemia, hypomagnesemia, or long QT syndrome [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 )]. Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 , 7.2 )]. Avoid food 2 hours before and 1 hour after taking...
What it is approved for
From the label in effect Sep 29, 2026.
Nilotinib Capsules is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) 1.1 Adult Patients With Newly Diagnosed Ph+ CML-CP Nilotinib Capsules is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna ® (nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Adult Patients With Resistant or Intolerant Ph+ CML-CP and CML-AP Nilotinib Capsules is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib. Additional pediatric use information is approved for Novartis Pharmaceuticals Corporation’s Tasigna ® (nilotinib) capsules. However, due to Novartis Pharmaceuticals Corporation’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Mechanism: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro , nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out of 33 mutations tested. Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20 to 60 nM), PDGFR (69 nM), c-KIT...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- NILOTINIB D-TARTRATE · NILOTINIB D-TARTRATE EQ 150MG BASE · CAPSULE, ORAL · Discontinued
- NILOTINIB D-TARTRATE · NILOTINIB D-TARTRATE EQ 200MG BASE · CAPSULE, ORAL · Discontinued
- NILOTINIB D-TARTRATE · NILOTINIB D-TARTRATE EQ 50MG BASE · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Nilotinib D-" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)Pivotal-lookingCompleted
Ariad PharmaceuticalsTakeda (TAK)
NCT01207440 · 449 participants · Start Sep 30, 2010 · Primary completion Dec 20, 2018
Drug: Ponatinib · For: Chronic Myeloid Leukemia; Ph+ Acute Lymphoblastic Leukemia
Sites: St Leonards, Australia; Woolloongabba, Australia; Adelaide, Australia · 42 sites in all
- A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young AdultsPivotal-lookingStatus unknown
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT02611492 · 265 participants (planned) · Start Apr 2016 · Primary completion Dec 2020
Drug: Nilotinib; Methotrexate and 7 more · For: Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
Sites: Paris, France
Asan Medical CenterAcademic, hospital or other
NCT00844298 · 91 participants · Start Jan 2009 · Primary completion Jun 2012
Drug: Nilotinib+mVPD · For: Leukemia
Sites: Daegu, South Korea; Goyang, South Korea; Jeollanam-do, South Korea · 16 sites in all
Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
NCT01883219 · 80 participants (planned) · Start Jun 2013 · Primary completion Jun 2016
Drug: TKIs · For: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia; Stem Cell Transplantation; Minimal Residual Disease
Sites: Guangzhou, China
Ulsan University HospitalAcademic, hospital or other
NCT01690065 · 46 participants (planned) · Start Sep 2012 · Primary completion Sep 2019
Drug: Nilotinib+AD induction · For: Chronic Myeloid Leukemia in Myeloid Blast Crisis; Untreated Adult Acute Myeloid Leukemia
Sites: Seoul, South Korea; Ulsan, South Korea
Novartis PharmaceuticalsNovartis (NVS)
NCT00756509 · 34 participants · Start Aug 29, 2008 · Primary completion Dec 18, 2024
Drug: Nilotinib · For: Gastrointestinal Stromal Tumors
Sites: Helsinki, Finland; Lyon, France; Munich, Germany · 10 sites in all
Mayo ClinicAcademic, hospital or other
NCT01806571 · 34 participants · Start Mar 12, 2015 · Primary completion Jul 31, 2017
Drug: Cytarabine; Daunorubicin Hydrochloride and 1 more · For: Untreated Adult Acute Myeloid Leukemia
Sites: Scottsdale, Arizona; Rochester, Minnesota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug intolerance430
- drug ineffective349
- drug resistance348
- diarrhoea338
- dyspnoea335
- fatigue325
- nausea306
- headache302
- myalgia281
- arthralgia272
- abdominal pain271
- pleural effusion270
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 12 |
| 2009 | 17 |
| 2010 | 19 |
| 2011 | 43 |
| 2012 | 95 |
| 2013 | 88 |
| 2014 | 154 |
| 2015 | 157 |
| 2016 | 215 |
| 2017 | 177 |
| 2018 | 267 |
| 2019 | 440 |
| 2020 | 375 |
| 2021 | 347 |
| 2022 | 323 |
| 2023 | 306 |
| 2024 | 365 |
| 2025 | 341 |
| 2026 | 322 |
Recalls
2 FDA enforcement reports for this application.
Feb 18, 2026 · Class III · Ongoing
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Feb 18, 2026 · Class III · Ongoing
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Cipla
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.